GlassScriptPhysician profile
Evan M Mulamba
NPI 1700539236
$1,515.30
in general payments reported to CMS, 2019-2025
24 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $948 · 2023: $300 · 2024: $130 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $302.15 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $167.02 | 2022-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $130.09 | 2024 | Spravato |
| Axsome Therapeutics, INC. | $126.30 | 2023 | Auvelity |
| Janssen Scientific Affairs, LLC | $124.98 | 2022 | |
| Neurocrine Biosciences, INC. | $109.08 | 2022-2023 | Ingrezza |
| Lundbeck LLC | $72.45 | 2022 | |
| Millicent US INC | $56.41 | 2025 | Femlyv |
| Alkermes, INC. | $56.11 | 2022 | |
| Neos Therapeutics, LP | $52.07 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.88 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.84 | 2022 | |
| Mayne Pharma Commercial LLC | $31.39 | 2025 | |
| Astellas Pharma US INC | $30.07 | 2025 | Veozah |
| Bausch Health US, LLC | $24.43 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $19.48 | 2025 | Phexxi, Solosec, Phexx |
| Corium, LLC | $19.21 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.19 | 2022 | |
| Almatica Pharma LLC | $18.59 | 2022 | |
| Owp Pharmaceuticals, INC. | $16.54 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.44 | 2023 | Xifaxan |
| Lilly USA, LLC | $14.69 | 2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $14.25 | 2023 | |
| Merck Sharp & Dohme LLC | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Mulamba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.